



The promises of quantitative systems pharmacology modelling for drug development



V.R. Knight-Schrijver^a, V. Chelliah^b, L. Cucurull-Sanchez^c, N. Le Novère^{a,*}

^aBabraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK

^bEuropean Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK

^cGlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK

ARTICLE INFO

Article history:

Received 22 June 2016

Received in revised form 8 September 2016

Accepted 19 September 2016

Available online 23 September 2016

Keywords:

Quantitative systems pharmacology

QSP

Drug discovery

Modelling

Systems biology

New therapeutic entity

ABSTRACT

Recent growth in annual new therapeutic entity (NTE) approvals by the U.S. Food and Drug Administration (FDA) suggests a positive trend in current research and development (R&D) output. Prior to this, the cost of each NTE was considered to be rising exponentially, with compound failure occurring mainly in clinical phases. Quantitative systems pharmacology (QSP) modelling, as an additional tool in the drug discovery arsenal, aims to further reduce NTE costs and improve drug development success. Through *in silico* mathematical modelling, QSP can simulate drug activity as perturbations in biological systems and thus understand the fundamental interactions which drive disease pathology, compound pharmacology and patient response. Here we review QSP, pharmacometrics and systems biology models with respect to the diseases covered as well as their clinical relevance and applications. Overall, the majority of modelling focus was aligned with the priority of drug-discovery and clinical trials. However, a few clinically important disease categories, such as *Immune System Diseases* and *Respiratory Tract Diseases*, were poorly covered by computational models. This suggests a possible disconnect between clinical and modelling agendas. As a standard element of the drug discovery pipeline the uptake of QSP might help to increase the efficiency of drug development across all therapeutic indications.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Introduction

1.1. The price of productivity

At the turn of the 21st century, a prevalent view of the pharmaceutical industry productivity was that compound attrition throughout the drug discovery pipeline was increasing [1, 2] and that the annual output of new therapeutic entities (NTEs) was in decline [3]. A broader picture, on the other hand, implies that there had been a tenuous growth in number of annual NTEs approved since 1940 (Fig. 1). NTEs are novel chemical and biological drugs where the active moiety has not previously been approved by the FDA. As a result, they are often used as a measure of pharmaceutical research and development (R&D) output [4]. Despite the apparent decline in NTEs seen over the last two decades, the long-term growth in NTE output appears to be unabated (Fig. 1). The primary concern within the pharmaceutical industry is that dramatic increases were seen

in the total cost of bringing each NTE to market [5, 6]; the cost of drug discovery was seen to increase exponentially [7]. However, the evidence suggests here as well that the cost per NTE might have reached a plateau by 2010 following the rise in approvals and may have even been in decline since [8, 9] (Fig. 2). In lieu of this perceived negative trend, there could be instead a positive shift in raw R&D output in the pharmaceutical industry.

The rapidly rising cost of drug discovery may have been, in part, caused by the increasing frequency of compound termination in the highly expensive clinical research phases. Although the cost per NTE may be decreasing (Fig. 2), the contribution of late-stage drug failure to pharmaceutical expenses remains substantial. Drug attrition which occurs during clinical trials stages is caused by unfavourable efficacy, lack of commercial viability and poor safety [10, 11]. To effectively combat this costly termination of drugs, the pharmaceutical industry has been keen to augment the drug discovery process with theoretical and computational modelling [12–18]. Models offer cheap predictive solutions for drug pharmacokinetics (PK), pharmacodynamics (PD) and patient population responses. Models are also capable of providing novel insights into fundamental biology which furthers our understanding of nature and diseases [19, 20].

* Corresponding author.

E-mail address: lenov@babraham.ac.uk (N. Novère).




Fig. 1. Total new therapeutic entity (NTE) approvals since 1938. New data since 2008 illustrates the recent positive shift in NTE output. The number of NTEs approved in 2014 and 2015 is surpassed only by 1996 when a backlog of new drug applications (NDAs) may have been rapidly processed following a change in regulations. Data was sourced from the Food and Drug Administration (FDA).

1.2. Pharmacokinetics, pharmacodynamics and pharmacometrics.

The models by Teorell [21, 22] are often regarded as the foundations of mathematical modelling in pharmacology [23]. PK modelling is largely focused on the absorption, distribution, metabolism and excretion (ADME) properties of compounds, i.e. what the body does to the drugs. It was not until the 1950s that the intrinsic drug activity or pharmacodynamics (PD), i.e. what the drug does to the body, was effectively considered in modelling. To understand and predict the complete effect of drug administration, both elements were combined as PK/PD models [24]. The first dedicated pharmacokinetics software, NONLIN, began distribution in 1969 and signalled the start of a busy period for PK/PD modelling. Multiple advancements in techniques and programs over two decades caught the interest of the FDA who then encouraged the use of quantitative modelling in drug development [25]. At this time, and possibly resulting from this sudden interest, kinetics-mediated drug attrition in clinical phases was dramatically reduced [10]. Traditional pharmacokinetics, pharmacodynamics and statistical pharmacometric models, based on empirical or semi-mechanistic representations, have more recently been complemented by physiologically-based pharmacokinetic (PBPK) models, using more accurate representations of the various body compartments. PBPK models incorporate drug-independent data such as tissue blood flow, which enables inter-compound predictions and inter-species translation [26, 27].




Fig. 2. The price of drug development from 1980 to 2014. An exponential increase in new therapeutic entity (NTE) cost is seen before 2008. The cost was calculated using R&D expenditures data given by PhRMA member companies [8] and annual Food and Drug Administration (FDA) reports on NTE approvals seen in Fig. 1. It is assumed that the given PhRMA members' expenditure proportionally represents the global expenditure over time and that these were adjusted for inflation.

Pharmacometric models are designed to predict the biological variability in patient populations which can be used to predict clinical trial outcomes. Lee et al. studied the success of pharmacological models in FDA approval decisions between 2000 and 2008 [28]. They show a six-fold increase in pharmacometric analyses over the nine years and suggest that the pharmacometric elements were essential for approval in the majority of NDAs [28–30]. The PK/PD success story in preclinical prediction and the continued value of pharmacometrics in clinical stages suggests that more sophisticated and mechanistic pharmacological modelling approaches may help to further reduce the current sources of late-stage attrition.

1.3. Mechanistic modelling with systems biology

For the better part of a century, computational modelling and simulation approaches have been essential in understanding biology. Simple simulations of biological systems as early as the giant squid axon model by Hodgkin and Huxley in 1952 [31] illustrate that the integration of such models with experiments can reveal novel emergent properties. The added value of computational models in driving hypotheses has then led to the generation of a separate field of study in its own right, systems biology. Heralded as one solution to understanding the 'data explosion' [32], the field has been embraced globally. Systems biology is the interpretation and study of biological networks as a holistic approach. The rationale is that the dynamic response of a whole system, such as the human body, to a stimulus is governed by the collective individual responses of all components of the system. Computational models are then necessary in systems biology because of the complex and multifaceted interactions which can be readily described by mathematical models but do not lend themselves to intuitive understanding.

In discussing the elements of systems biology, Kitano [33] points out that, to fully understand biology at a system-level, one needs to determine the structure of the system. This encompasses the biochemical and physical entities in a network of interactions. Furthermore, the level of understanding also requires knowledge of the time-dependent network interconnectivity. A simple definition has therefore been proposed for systems biology models using the following criteria [34]: A functional model must contain

1. The components that constitute the biological system of interest.
2. The temporal dynamic nature of each individual component of this system.
3. The interconnectivity and temporal dynamic interaction between these components.

Quantitative systems pharmacology (QSP) draws its inspiration from the need for biologically mechanistic modelling, the success of pharmacometrics modelling and systems biology.

1.4. Quantitative systems pharmacology

Aiming to incorporate detailed biological processes within PK/PD and PBPK, QSP is the application of systems biology modelling to drug discovery. A working definition was provided initially by Allerheiligen in 2010 [35] and extensively by Sorger et al. in an NIH white paper in 2011 [36]. In brief, QSP is focused on the drug-gability of targets within biological systems. It relies on dynamic mathematical and computational analyses which integrate multiple experimental data and, similar to systems biology, QSP models are concerned with the emergent properties found in detailed representations of biological systems. Furthermore, the output of QSP is a knowledge-base or model with predictive capabilities to enhance drug discovery. With this summary in mind, an additional criterion can be appended to the systems biology model description [34] to

define QSP. A quantitative systems pharmacology model should also include

4. The modulation of components and dynamic interactions by putative therapy or compound(s).

In practice, this already appears to be a key aspect of the majority of systems biology analyses. However, this is the principal rationale behind the task of constructing a QSP model. Given the criteria presented here, the construction of a QSP model is reliant upon the existence of quantitative temporal data. This reliance has been a limiting factor for the development and use of mechanistic modelling in drug development in the past. Lately however, the accumulation of relevant data has enabled a reasonable use of QSP models, at least in basic and preclinical research. The match was struck in a white paper published in 2011 [36]. Following this, the quantity of published articles describing systems pharmacology models, as well as reviews of their utility, has grown substantially. As shown in Fig. 3, although the term *systems pharmacology* made a notable appearance in papers from 2010, a 9-fold increase was seen between 2011 and 2013 with 9 to 82 articles published in each year respectively.

This increased interest may indicate that the pharmaceutical industry is beginning to integrate systems-level modelling as a standard element of the drug discovery pipeline. Nonetheless, the mainstream application of QSP modelling and the bringing of modelling into the clinical stages of drug development still requires further effort. QSP modelling has to effectively address the clinical requirements, such as descriptions of statistical patient variability or long-term disease progression, and improve the accessibility of modelling for clinicians and pharmaceutical companies [37]. Further work in perfecting QSP modelling is needed for meeting all expectations. From target identification through to approval, QSP is proposed as the required tool in continuous program evaluation for predicting and minimising the high cost of late-stage drug attrition [35]. How has the mantle been upheld so far? Recent reviews have discussed the potential goals, methods and application of QSP [38–41]. The present mini-review is a brief attempt to examine the current scope and extent of the QSP modelling field.

2. The scope of QSP models

A short examination makes clear that a simple search query, such as that performed in Fig. 3, is not capable of truly retrieving all QSP models in literature. Such an attempt frequently returns reviews and static network analyses but often fails to capture research




Fig. 3. The rise of publications in Systems Pharmacology. A simple search query in Pubmed was used to return all articles explicitly containing “systems pharmacology” in the title, abstract or key words sections ($n = 352$). Not all abstracts refer to systems pharmacology models. The expected number of articles published in 2016 (*) is a simple prediction based on the number of articles currently available in 2016 ($72 \times (12/7)$). Performed on the 15th of July 2016.

which can otherwise, given the criteria in 1.3–1.4, be described as systems pharmacology modelling. It is also unrealistic to expect “systems pharmacology” or “QSP” to appear explicitly in the more dated research abstracts. In fact, we can see that the term “systems pharmacology” was not mentioned in Pubmed until 2004 (Fig. 3). Therefore, in an effort to capture the spread of QSP modelling across therapeutic areas and indications, we constructed a more complex, wider and more precise, text mining query to recall relevant research abstracts from Medline dated from 1965 to 2015. The query included a large set of positive key terms including, amongst others, *systems pharmacology* and *mathematical model* (The full text mining analysis will be presented in a more detailed manner in a separate research paper). Initially, a set of negative terms were also included. However these substantially decreased the recall of the positive control and reduced the total number of modelling abstracts retrieved. The abstracts and clinical studies for this time period were annotated with Medical Subject Headings (MeSH) 2014 and categorised into the separate disease branches.

The result of this analysis shows that while generally matching the agenda of clinical trials, in a few disease categories, the focus of modelling literature is poorly aligned with clinical interest. For example, Fig. 4 shows that the fractions of documents discussing *Immune System Diseases*, *Respiratory Tract Diseases* and *Digestive System Diseases* were approximately two-fold greater in clinical studies than in the modelling literature. Therefore, certain diseases may lack an extensive modelling arsenal. Conversely, categories such as *Bacterial Infections and Mycoses* or *Congenital, Hereditary, and Neonatal Diseases and Abnormalities* were commonplace in modelling literature but were comparatively much less prevalent in clinical trials. Unsurprisingly, there appeared to be little clinical interest in *Animal Diseases* (Fig. 4).

The BioModels database was included in this assessment as a positive control for dynamic biological models since it is the largest public repository of curated mathematical models in systems




Fig. 4. Clinical trials and modelling. Clinical studies, modelling literature and positive control abstracts were labelled with diseases by their in-text occurrence. Each disease was categorised under MeSH 2014 disease branches and documents without any disease were omitted. The fraction of documents labelled with each disease was calculated using the n_d for each corpora (Table 1). The software I2E[®] 4.2 (Linguamatics) was used to run the query and perform the MeSH term extraction.

biology [42, 43]. The query retrieved 76% of all abstracts with models stored in BioModels. However, only 35% of the models stored in BioModels were labelled with a disease term (Table 1). Note that a given document could be tagged for multiple disease categories. One caveat of this data set is that it may not be enriched for criterion 4 in defining a QSP model. Whereas the image resulting from the text mining analysis may not portray the full scope of QSP or pharmacological modelling, the fraction of positive control articles retrieved suggests that the recall of models by the query was reasonable. However, samples indicate that, whilst 18% of total Medline abstracts were systems modelling papers, only 5% of the total abstracts retrieved were pharmacological models.

The current approach made no distinction between QSP and PK/PD or pharmacometrics models and, as the majority of retrieved documents were not systems biology or pharmacology, a poor overall precision was expected. Since this study only considered abstracts available in Medline, it did not take into account unpublished in-house modelling works and published materials not indexed in Medline. Moreover, explicit textual references to a disease were required for a document to be categorised within MeSH disease branches. Therefore, high-resolution models that mentioned specific genes, proteins or pathways without explicitly mentioning the disease were missed. Finally, other errors may lie within the classification itself. The MeSH branch *Pathological Conditions, Signs and Symptoms* was omitted due to its ambiguous nature. Annotation of MeSH terms can be inconsistent or false and some diseases, often tissue-specific cancers, fall into multiple categories. Clearly the current analysis can be improved on the side of precision.

All that said, with a few exceptions, the spread of diseases covered by BioModels broadly spanned the spectrum of models mentioned in Medline. A concerted effort within the BioModels database has focused on models of diabetes [44]. This may explain why the focus of *Nutritional and Metabolic Diseases* or *Endocrine System Diseases* in clinical studies is closer to that of the BioModels database than the overall modelling literature (Fig. 4).

3. The extent of QSP models

The consistent application of computational modelling analyses in NDA success is clear evidence for the beneficial application of theoretical models in drug discovery [29]. QSP models also provide a method to further understand the biological mechanisms and predict the ideal targets, drug dose and toxicological properties. This improves the confidence in drug efficacy and safety profiles prior to success of an NDA. One particular and compelling use case of QSP modelling is the application of a calcium homeostasis model by Peterson and Riggs [45] [BioModels Database: MODEL1604270004]. Khurana et al. adapted a publicly accessible version of the model specifically for the FDA review of a Biologics License Application in 2014 [46]. This model was then used to explore the kinetics and drug administration of a recombinant human parathyroid hormone.

Simulations demonstrated that the dose regimens or drug properties could be optimised to provide a better adherence to the therapeutic window. In fact, a clinical study has been filed this year following the conclusions drawn from the QSP dose optimisation.

Below, we present several other example cases illustrating the application and utility of QSP models in diseases of clinical priority.

3.1. Neoplasms

Neoplasms were labelled in 27% of clinical studies, confirming that oncology is highest on the clinical agenda (Fig. 4). QSP has analysed the spatio-temporal dynamics of tumours with models of tumour growth, drug delivery and intervention efficacy [47, 48]. For instance, the QSP model by Sharan and Woo [49] [BioModels: MODEL1604270003] integrated aspects of growth, signalling and biomarkers. The model explored treatment with the anti-vascular endothelial growth factor (VEGF) agent sunitinib. A further modelling exercise combined the mechanistic signalling module with additional clinical responses [50]. This highlighted the benefits of effective biomarker monitoring and dose optimisation in complex cancer therapy. Preclinical analyses of drug combinations is one application of modelling efforts in cancer. A model by Zhu et al. [51] [BioModels: MODEL1604270000, MODEL1604270001] assessed the dose patterns of two anti-pancreatic cancer molecules, gemcitabine and birinapant in cell culture. Although the model was not further translated to an organismal scale, it illustrated how preclinical modelling can shortlist optimal dose schedules for clinical trials in contrast to current regimens [52].

3.2. Nervous system diseases

Drug development in central nervous system (CNS) diseases such as Alzheimer's disease has been plagued by poor translation of efficacy from animal models into humans [53, 54]. Low predictive precision in animal models is often caused by significant differences in neuronal circuitry between species as well as unknown CNS biology and disease pathology. Using mathematical interpretations of the known processes, systems modelling is capable of testing multiple hypotheses to predict the possible mechanisms of drug action. The quantifiable nature of this approach is also ideal as a translational step or compliment to animal models [55]. For example, by humanising parameters derived from animal models in a dynamic network, it may be possible to predict the outcome of an intervention in humans before clinical trial commencement. This further be used to specify the compound properties, if any, required for drug success in humans where a compound may not appear to be efficacious. Low patient efficacy in clinical trials of drugs for CNS diseases means that early indication of clinical effect, or lack thereof, is highly important in decision making. For instance, Nicholas et al. [56] developed a QSP model to evaluate the potential of 5-HT₄ receptors as a target to treat Alzheimer's disease. They coupled a simple cortical neuron model with a ligand competition module for 5-HT₄ receptor binding. The model demonstrated that low efficacy 5-HT₄R agonists would worsen the disease state when assessing the clinical outcome of a serotonergic agonist in scopolamine-induced cognitive deficit patients. It was shown that a threshold intrinsic activity of the agonist-receptor complex was necessary to modulate the pathway for improvements on patient cognition.

Roberts et al. [57] developed a similarly structured model with the NEURON software and used a QSP approach to study the attenuation of parkinsonian hypokinetic motor symptoms. The model integrates the neuronal circuitry of the cortico-striatal-thalamic loop with ligand-receptor competition dynamics. The local field potential of the subthalamic nuclei was used as a clinical marker. Calibrated using the polypharmacology of 43 anti-psychotic drug combinations,

Table 1

The three corpora used in this analysis. Due to technical limitations, fewer documents were labelled with diseases (n_d) than the total number of documents in each corpus (n_t).

Corpus	n_t	n_d
Clinical studies ^a	177,609	147,235
Modelling literature ^b	215,097	85,676
Positive control literature ^c	687	244

n_t total number of documents; n_d number of documents labelled with a disease.

^a clinicaltrials.gov.

^b Medline – text mining query for models.

^c BioModels database.

the clinical outcomes of dopamine, NMDA, adenosine, 5-HT modulators and even placebo treatments were predicted in simulations. This method quantified which targets could generate the optimal response and which compounds offered the greatest therapeutic potential. When directly parametrised with human data, simple neuronal circuitry models mitigate the problems arising from species translation.

3.3. Cardiovascular diseases

Mechanistic models have greatly contributed to the fundamental understanding of cardiovascular diseases from signalling [58] to fluid dynamics [59]. In therapeutics, models of drug-eluting arterial stents have been used to explore the mechanisms and increase efficiency of stent development [60]. Garmaroudi et al. [61] presented a combinatorial approach to pathway perturbation in cardiovascular disease signalling. They used QSP modelling to evaluate options of polypharmacology in minimising adverse reactions and countering biological redundancy; systems modelling enabled researchers to examine the network-wide effects of multi-target perturbations. The model assessed the ability of several compounds to restore impaired nitric oxide-cyclic guanosine 3',5'-monophosphate (NO[•]-cGMP) signalling. The authors simulated the dynamic elevation of cGMP resulting from 377 different individual, double or triple parameter perturbation combinations. One optimal triple reaction perturbation was predicted to increase cGMP substantially beyond all other combinations. The predictions were then validated *in vitro* using clinically available compounds.

Cardiotoxicity is associated with cardiovascular diseases, and an important hurdle in drug discovery. Individual drugs and drug-drug interactions can stimulate cardiovascular arrhythmia as an adverse reaction. Computational modelling efforts have been launched to define the mechanisms underlying the effects of a multitude of compounds on arrhythmic events as well as their therapeutic windows for a multitude of compounds [62]. In forming QSP models, the *in silico* reconstruction of known cardiac biology could be combined with the observed clinical outcomes to predict drug-mediated cardiovascular diseases. For example, a PBPK model combined with a response model of cardiomyocyte ion-channels [63] was used to predict the drug-drug interaction of domperidone and ketoconazole on QT prolongation. These cardiovascular disease examples demonstrate that QSP modelling can explore the promising prospects of polypharmacy in drug-discovery [64].

3.4. Nutritional and metabolic diseases

The global incidence of nutritional and metabolic diseases such as diabetes is steadily rising. Clinical efforts to understand and treat diabetes have been mirrored by a large plethora of models comprehensively summarised by Ajmera et al. [44]. The scales of these models range from intracellular signalling to systemic homeostasis and disease progression. One recent QSP model explored the current assumptions underlying the therapeutic mechanism of interleukin-1 β (IL-1 β) blockade in type-2 diabetes mellitus (T2DM) [65] [BioModels: MODEL1604 270002]. The authors described a QSP disease progression model of T2DM including a model of β -cell function. The simulation of therapeutic perturbations explored the facets of anakinra treatment. The model predicted that improved β -cell function is responsible for its short-term efficacy. Additionally, predictions estimated that a persistent improvement in disease state was governed by an increased β -cell mass but only after sustained therapy. They concluded that (IL-1 β) suppression over several years may be required to reach a significant therapeutic endpoint.

3.5. Diseases with nascent QSP

Contrary to cancer, CNS and cardiovascular diseases, several disease categories have rarely been studied using computational modelling. However, the situation is changing in a few cases.

A recent platform was designed to simulate the systemic immune response to pathological disruptions. The fully-integrated immune response model (FIRM) describes the effects of several cytokines upon a variety of cell types [66] [BioModels: BIOMD000000608]. The application of FIRM was demonstrated on tuberculosis, tumour rejection and pathogen response. Adoption of FIRM as a QSP environment could prove useful in predicting the risk of compromising the immune system by compounds with immunosuppressive properties.

Substantial clinical interest in respiratory tract diseases has encouraged the construction of a QSP model for exploring the mechanisms underlying the effects of a 5-lipoxygenase inhibitor, Zileuton, on asthma [67] [BioModels: BIOMD000000490]. The model explores target comparison, proposes an emergent explanation for clinical data and discusses optimal dose strategies.

In the gastrointestinal system, modelling the interaction between gut and drugs is obviously key to optimising drug oral administration. However, only a very small fraction of QSP research focuses on diseases of the digestive systems (note that we are only talking about QSP models, agent-based models typically use the gut epithelium as the tissue of choice [68]). Modelling intestinal *C. difficile* infection, Leber et al. generated a model exploring the immune response of the gut [69] [BioModels: BIOMD000000583]. The model predicts that suppression of the gut immune response may, counter-intuitively, aid recovery from infection and perhaps assist in fecal transplant therapy. Expansion of QSP studies into sparsely modelled (but otherwise clinically important) diseases may provide ways to reduce late-stage attrition. The ease at which modelling can be performed will be crucial to achieve this expansion.

4. Modelling is easy these days

Common modelling approaches used in systems biology can be easily applied to QSP, and many tools are available for the curious researcher [70, 71]. For example, data obtained from open-access databases of biological networks such as KEGG Pathways [72] or Reactome [73] can be used with programs like Cytoscape [74] and CellDesigner [75]. To describe a dynamic system, mathematical equations can be defined and solved in a wide variety of freely available environments such as Copasi [76], R [77] or Octave [78]. Proprietary environments such as SimBiology[®] (part of MATLAB[®] [79]) are also often used for model development. Finally, some commercial drug development programs specialise in predicting the ADME properties of compounds, like Simcyp [80] or Gastroplus[™].

A typical modelling work flow relies on several software tools and the communication between tasks or between researchers must be seamless. As mentioned by Leil and Ermakov [81], the lack of acceptable standards and tools could hinder the emergence and commonplace use of QSP in drug discovery. Standardisation efforts facilitate model sharing, reproducibility of their analysis and ultimately domain repute and progression. In systems biology the Systems Biology Markup Language (SBML) [82] has been a *de facto* standard for more than a decade. Developed by the community, it is supported by hundreds of software tools, databases and modelling platforms. The pharmacometrics community recently developed the Pharmacometrics Markup Language (PharmML) [83]. PharmML was developed through the DDMoRe consortium [84], a partnership between academic partners and the pharmaceutical industry. It was designed as a common format or *lingua franca* between a large variety of popular pharmacometrics tools and aims at establishing a standard language for PK/PD and QSP modelling. Common formats such as

PharmML and SBML encourage the sharing of models, fuelling scientific collaboration. This also promotes model progression, reuse and much needed training of new translational scientists in both academia and industry.

The DDMoRe project also aims to create and improve open software resources available for modelling in drug development. For instance, it provides a freely available repository for sharing pharmacological models (<http://repository.ddmore.eu/>). BioModels [42] itself provides an increasing number of curated pharmacological models, including PK/PD models (the models mentioned in this review are freely available in BioModels). Placing models in open-access repositories increases their visibility and the availability of their code allows them to be reused. This is of great importance as it may help to concentrate computational efforts and provide clinically relevant models to researchers.

5. Summary and outlook

The number of systems pharmacology articles published has increased dramatically since 2011 bringing an array of quantitative models (Fig. 3). These models are capable of capturing dynamic systems at varying scales, simulating the purported effect of drugs and strategies used in clinic, and assessing the validity of our current biological understanding and clinical outcomes. Here we have briefly discussed examples of the application and extent of current QSP modelling, in particular for disease categories rich with models. A preliminary evaluation of the disease focus suggests that the efforts of modelling could be align better with the clinic.

Both *Cardiovascular diseases* and *Nervous systems diseases* are prone to frequent compound failure [12]. In these complex disease categories, high drug attrition rates may partially explain the popularity of seeking a modelling approach. A traditionally large modelling effort is, however, not the assurance of success. While *Neoplasms* is the most popular disease category for modelling, oncology has the highest compound failure rate in phase II and III trials [10, 12, 85]. An explanation could be the large number of post-mortem models, built following terminated clinical trials. Whilst these are useful in both model validation and for identifying the causes of termination, failure of the compounds may have been foreseen by the earlier use of modelling.

In a follow-up review on the FDA's application of the calcium homeostasis model [45, 46], Peterson and Riggs suggested that the QSP modelling field will be emboldened by milestone cases such as the Natpara® BLA in 2014 [39]. However, they also stressed that several regulatory factors impede a sudden embrace of QSP models in the pharmaceutical domain. Notably, the proper education and training of future QSP scientists is an important prerequisite for industrial interest, as discussed in detail by Sorger et al. [36]. Paramount however, and governing the rate at which QSP is adopted, is the frequency at which key models are successfully put to the test. The accumulation of positive use cases may encourage a shift towards the much needed earlier applications of modelling in the drug development pipeline.

Community-wide interest in QSP is nevertheless increasing. Following the two NIH QSP workshops in 2008 and 2010, reviews have been published annually which offer in-depth discussions on the range of applications, examples and insights offered by QSP modelling [38, 40, 81, 86–89]. A UK Quantitative Systems Pharmacology Network now funded by the EPSRC aims to bring together experimental and theoretical scientists in both academia and industry. Within the QSP community it is clear that QSP is not just aimed at developing single-use models, but that it is a central and core component of the drug development pipeline. The real worth of QSP is perhaps in integrating the multiple aspects of a compound's development, incorporating the fundamental disease

biology, pharmacokinetics and pharmacodynamics including toxicity and clinical outcomes. QSP models could act as central knowledge repositories, improving data communications between collaborating teams. Such a radical pipeline reshuffle may be key to refreshing the drug discovery paradigm.

It is heartening to note the recent positive trend in annual NTE output. Partial responsibility may lie in the increased application of pharmacometrics in NDA approvals [28] with 80–90% of drugs being successful in the FDA review process [7, 12]. However, the fraction of drugs that make it through clinical trials to the NDA stage is only 12% which contributes to the substantial cost of pharmaceutical R&D [12]. QSP can address the efficacy and toxicity which causes this attrition by exploring the pathological mechanisms underlying the disease. The models provided by QSP can be used to document a drug's likelihood of approval which can inform decision making throughout the preclinical and clinical stages. Therefore, instead of resorting to post-mortem analysis, the early and preventative incorporation of QSP modelling into the drug discovery process can increase R&D efficiency by regularly evaluating a compound's viability.

Just as PK models already drove down costly attrition, QSP models, as a predictive platform, may further reduce late-stage drug failure in tomorrow's drug discovery pipeline, the impact of which can only be positive for industry and patients alike.

Funding

Research was funded by a Biotechnology and Biosciences Research Council (BBSRC) industrial CASE studentship in collaboration between the Babraham Institute and GlaxoSmithKline Research & Development Ltd (NLN, BBSRC Institute Strategic Programme [BBS/E/B/000C0419]; VKS, BBSRC-GSK CASE studentship [BB/L502224/1]).

References

- [1] Pammolli, F Magazzini, L Riccaboni, M The productivity crisis in pharmaceutical R&D, *Nat Rev Drug Discov* 10 (6) (2011) 428–38. <http://dx.doi.org/10.1038/nrd3405>.
- [2] Frantz, S 2003 approvals: a year of innovation and upward trends, *Nat Rev Drug Discov* 3 (2) (2004) 103–5. <http://dx.doi.org/10.1038/nrd1327>.
- [3] Munos, B Lessons from 60 years of pharmaceutical innovation, *Nat Rev Drug Discov* 8 (12) (2009) 959–68. <http://dx.doi.org/10.1038/nrd2961>.
- [4] Branch, SK Agranat, I “New drug” designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity, *J Med Chem* 57 (21) (2014) 8729–65. <http://dx.doi.org/10.1021/jm402001w>.
- [5] Scannell, JW Blanckley, A Boldon, H Warrington, B Diagnosing the decline in pharmaceutical R&D efficiency, *Nat Rev Drug Discov* 11 (3) (2012) 191–200. <http://dx.doi.org/10.1038/nrd3681>.
- [6] Cohen, FJ Macro trends in pharmaceutical innovation, *Nat Rev Drug Discov* 4 (1) (2005) 78–84. <http://dx.doi.org/10.1038/nrd1610>.
- [7] DiMasi J A. Innovation in the pharmaceutical industry: new estimates of R&D costs, In: R&D cost study briefing, Tufts Center for the Study of Drug Development (TCSDD), November 18, 2014. Available from: http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing_on_RD_cost_study_-_Nov_18,_2014.pdf.
- [8] 2015 Biopharmaceutical research industry profile. Pharmaceutical Research and Manufacturers of America (PhRMA), 2015. Available from: http://www.phrma.org/sites/default/files/pdf/2015_pharma_profile.pdf.
- [9] Summary, Novel Drugs U.S. Food and Drug Administration Center of Drug Evaluation and Research, 2015, 2015. Available from: <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM485053.pdf>.
- [10] Kola, I Landis, J Can the pharmaceutical industry reduce attrition rates? *Nature reviews Drug discovery* 3 (8) (2004) 711–6. <http://dx.doi.org/10.1038/nrd1470>.
- [11] Waring, MJ Arrowsmith, J Leach, AR Leeson, PD Mandrell, S Owen, RM An analysis of the attrition of drug candidates from four major pharmaceutical companies, *Nat Rev Drug Discov* 14 (7) (2015) 475–86. <http://dx.doi.org/10.1038/nrd4609>.
- [12] Hay, M Thomas, DW Craighead, JL Economides, C Rosenthal, J Clinical development success rates for investigational drugs, *Nat Biotechnol* 32 (1) (2014) 40–51. <http://dx.doi.org/10.1038/nbt.2786>.
- [13] Cook, D Brown, D Alexander, R March, R Morgan, P Satterthwaite, G Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework, *Nat Rev Drug Discov* 13 (6) (2014) 419–31. <http://dx.doi.org/10.1038/nrd4309>.

- [14] Marshall, S Burghaus, R Cosson, V Cheung, S Chenel, M Good practices in model-informed drug discovery and development: practice, application, and documentation, *CPT: Pharmacometrics & Syst Pharmacol* 5 (3) (2016) 93–122. <http://dx.doi.org/10.1002/psp4.12049>.
- [15] Visser, SAG de Alwis, DP Kerbusch, T Stone, JA Allerheiligen, SRB Implementation of quantitative and systems pharmacology in large pharma, *CPT, Pharmacometrics Syst Pharmacol* 3 (10) (2014) e142. <http://dx.doi.org/10.1038/psp.2014.40>.
- [16] Milligan, PA Brown, MJ Marchant, B Martin, SW van der Graaf, PH Model-based drug development: a rational approach to efficiently accelerate drug development, *Clin Pharmacol Ther* 93 (6) (2013) 502–14. <http://dx.doi.org/10.1038/clpt.2013.54>.
- [17] Visser, SAG Manolis, E Danhof, M Kerbusch, T Modeling and simulation at the interface of nonclinical and early clinical drug development, *CPT: Pharmacometrics & Syst Pharmacol* 2 (2) (2013) e30. <http://dx.doi.org/10.1038/psp.2013.3>.
- [18] Visser, SA Aurell, M Jones, RD Schuck, VJ Egnell, A-C Model-based drug discovery: implementation and impact, *Drug Discov Today* 18 (15–16) (2013) 764–75. <http://dx.doi.org/10.1016/j.drudis.2013.05.012>.
- [19] Brodland, GW How computational models can help unlock biological systems, *Semin Cell Dev Biol* 47–48 (2015) 62–73. <http://dx.doi.org/10.1016/j.semcdb.2015.07.001>.
- [20] Kumar, N Hendriks, BS Janes, KA de Graaf, D Lauffenburger, DA Applying computational modeling to drug discovery and development, *Drug Discov Today* 11 (17–18) (2006) 806–11. <http://dx.doi.org/10.1016/j.drudis.2006.07.010>.
- [21] Teorell, T Kinetics of distribution of substances administered to the body, I: the extravascular modes of administration, *Arch Int Pharmacodyn Ther* 57 (1937) 205–25.
- [22] Teorell, T Kinetics of distribution of substances administered to the body, II: the intravascular modes of administration, *Arch Int Pharmacodyn Ther* 57 (1937) 226–40.
- [23] Paalzow, LK Torsten teorell, the father of pharmacokinetics, *Ups J Med Sci* 100 (1) (1995) 41–6. <http://dx.doi.org/10.3109/03009739509178895>.
- [24] Benet, LZ Foreword., in: NR Cutler, JJ Sramek, PK Narang (Eds.), *Pharmacodynamics and drug development: perspectives in clinical pharmacology*, Chichester: Wiley, 1994, pp. xiii–xv.
- [25] Rohatagi, S Martin, NE Barrett, JS Applications of pharmacokinetic principles in drug development, Ch. *Pharmacokinetic/Pharmacodynamic Modeling in Drug Development*, Springer, US, Boston, MA, 2004, 333–72. http://dx.doi.org/10.1007/978-1-4419-9216-1_11.
- [26] Edginton, AN Theil, F-P Schmitt, W Willmann, S Whole body physiologically-based pharmacokinetic models: their use in clinical drug development, *Expert Opin Drug Metab Toxicol* 4 (9) (2008) 1143–52. <http://dx.doi.org/10.1517/17425255.4.9.1143>.
- [27] Espié, P Tytgat, D Sargentini-Maier, M-L Poggesi, I Watelet, J-B Physiologically based pharmacokinetics (PBPK), *Drug Metab Rev* 41 (3) (2009) 391–407. <http://dx.doi.org/10.1080/10837450902891360>.
- [28] Lee, JY Garnett, CE Gobburu, JV Bhattaram, VA Brar, S Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008, *Clin Pharmacokinet* 50 (10) (2011) 627–35. <http://dx.doi.org/10.2165/11593210-000000000-00000>.
- [29] Bhattaram, VA Bonapace, C Chilukuri, DM Duan, JZ Garnett, C Impact of pharmacometric reviews on new drug approval and labeling decisions—a survey of 31 new drug applications submitted between 2005 and 2006, *Clin Pharmacol Ther* 81 (2) (2007) 213–21. <http://dx.doi.org/10.1038/sj.cpt.6100051>.
- [30] Bhattaram, VA Booth, BP Ramchandani, RP Beasley, BN Wang, Y Tandon, V Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications, *AAPS J* 7 (3) (2005) E503–E512. <http://dx.doi.org/10.1208/aapsj070351>.
- [31] Hodgkin, AL Huxley, AF A quantitative description of membrane current and its application to conduction and excitation in nerve, *J Physiol (Lond)* 117 (4) (1952) 500–44.
- [32] Mabry, PL Making sense of the data explosion: the promise of systems science, *Am J Prev Med* 40 (5 Suppl 2) (2011) S159–61. <http://dx.doi.org/10.1016/j.amepre.2011.02.001>.
- [33] Kitano, H Systems biology: a brief overview, *Science* 295 (5560) (2002) 1662–4. <http://dx.doi.org/10.1126/science.1069492>.
- [34] Albert, R Network inference, analysis, and modeling in systems biology, *Plant Cell* 19 (11) (2007) 3327–38. <http://dx.doi.org/10.1105/tpc.107.054700>.
- [35] Allerheiligen, SRB Next-generation model-based drug discovery and development: quantitative and systems pharmacology, *Clin Pharmacol Ther* 88 (1) (2010) 135–7. <http://dx.doi.org/10.1038/clpt.2010.81>.
- [36] Sorger, PK Allerheiligen, SR Abernethy, DR Altman, RB Brouwer, KL Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms, An NIH white paper by the QSP workshop group, NIH Bethesda, 2011, pp. 1–48.
- [37] Nyman, E Rozendaal, YJW Helmlinger, G Hamrén, B Kjellsson, MC Requirements for multi-level systems pharmacology models to reach end-use: the case of type 2 diabetes, *Interface Focus* 6 (2) (2016) 20150075. <http://dx.doi.org/10.1098/rsfs.2015.0075>.
- [38] Agoram, BM Demin, O Integration not isolation: arguing the case for quantitative and systems pharmacology in drug discovery and development, *Drug Discov Today* 16 (23–24) (2011) 1031–6. <http://dx.doi.org/10.1016/j.drudis.2011.10.001>.
- [39] Peterson, MC Riggs, MM FDA advisory meeting clinical pharmacology review utilizes a quantitative systems pharmacology (QSP) model: a watershed moment? *CPT Pharmacometrics Syst Pharmacol* 4 (3) (2015) e00020. <http://dx.doi.org/10.1002/psp4.20>.
- [40] van der Graaf, PH Benson, N Systems pharmacology: bridging systems biology and pharmacokinetics-pharmacodynamics (PKPD) in drug discovery and development, *Pharm Res* 28 (7) (2011) 1460–4. <http://dx.doi.org/10.1007/s11095-011-0467-9>.
- [41] Bai, JPF Fontana, RJ Price, ND Sangar, V Systems pharmacology modeling: an approach to improving drug safety, *Biopharm Drug Dispos* 35 (1) (2013) 1–14. <http://dx.doi.org/10.1002/bdd.1871>.
- [42] Le Novère, N Bornstein, B Broicher, A Courtot, M Donizelli, M BioModels database: a free, centralized database of curated, published, quantitative kinetic models of biochemical and cellular systems, *Nucleic Acids Res* 34 (Database issue) (2006) D689–D691. <http://dx.doi.org/10.1093/nar/gkj092>.
- [43] Chelliah, V Juty, N Ajmera, I Ali, R Dumousseau, M Biomodels: ten-year anniversary, *Nucleic Acids Res* 43 (2015) D542–D548. <http://dx.doi.org/10.1093/nar/gku1181>.
- [44] Ajmera, I Swat, M Laibe, C Novère, NL Chelliah, V The impact of mathematical modeling on the understanding of diabetes and related complications, *CPT: Pharmacometrics & Syst Pharmacol* 2 (7) (2013) e54. <http://dx.doi.org/10.1038/psp.2013.30>.
- [45] Peterson, MC Riggs, MM A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling, *Bone* 46 (1) (2010) 49–63. <http://dx.doi.org/10.1016/j.bone.2009.08.053>.
- [46] Khurana, M Mehrotra, N Zadezensky, I Clinical pharmacology assessment: adequacy of natpara dosage regimen in treatment of hypothyroidism, *Endocrinologic and metabolic drugs advisory committee meeting 2014*, endocrinologic and metabolic drugs advisory committee, office of clinical pharmacology, 2014, pp. 136–44.
- [47] Kazmi, N Hossain, MA Phillips, RM A hybrid cellular automaton model of solid tumor growth and bioreductive drug transport, *IEEE/ACM Trans Comput Biol Bioinform* 9 (6) (2012) 1595–606. <http://dx.doi.org/10.1109/TCBB.2012.118>.
- [48] Au, JL Yeung, BZ Wientjes, MG Lu, Z Wientjes, MG Delivery of cancer therapeutics to extracellular and intracellular targets: determinants, barriers, challenges and opportunities, *Adv Drug Deliv Rev* 97 (2016) 280–301. <http://dx.doi.org/10.1016/j.addr.2015.12.002>.
- [49] Sharan, S Woo, S Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach, *CPT Pharmacometrics Syst Pharmacol* 3 (2014) e139. <http://dx.doi.org/10.1038/psp.2014.36>.
- [50] Sharan, S Woo, S Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities, *Front Pharmacol* 6 (2015) 33. <http://dx.doi.org/10.3389/fphar.2015.00033>.
- [51] Zhu, X Straubinger, RM Jusko, WJ Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells, *J Pharmacokinet Pharmacodyn* 42 (5) (2015) 477–96. <http://dx.doi.org/10.1007/s10928-015-9429-x>.
- [52] Tetralogic pharmaceuticals, dose escalation, combination chemotherapy safety study of birinapant (TL32711), in subjects with advanced or metastatic solid tumors, *ClinicalTrials.gov* [Internet], Bethesda (MD): National Library of Medicine (US), 2010 - [cited 2016 April 18], Available from NLM Identifier: NCT01188499.
- [53] Geerts, H Spiros, A Roberts, P Carr, R Has the time come for predictive computer modeling in CNS drug discovery and development? *CPT: Pharmacometrics & Syst Pharmacol* 1 (11) (2012) e16. <http://dx.doi.org/10.1038/psp.2012.17>.
- [54] Franco, R Cedazo-Minguez, A Successful therapies for Alzheimer's disease: why so many in animal models and none in humans? *Front Pharmacol* 5 (2014) 146. <http://dx.doi.org/10.3389/fphar.2014.00146>.
- [55] Geerts, H Of mice and men, *CNS Drugs* 23 (11) (2009) 915–26. <http://dx.doi.org/10.2165/11310890-000000000-00000>.
- [56] Nicholas, T Duvvuri, S Leurent, C Raunig, D Rapp, T Systems pharmacology modeling in neuroscience: prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial, *Adv in Alzheimer's Dis* 02 (03) (2013) 83–98. <http://dx.doi.org/10.4236/aad.2013.23012>.
- [57] Roberts, P Spiros, A Geerts, H A humanized clinically calibrated quantitative systems pharmacology model for hypokinetic motor symptoms in Parkinson's disease, *Front Pharmacol* 7 (2016) <http://dx.doi.org/10.3389/fphar.2016.00006>.
- [58] Yang, JH Saucerman, JJ Computational models reduce complexity and accelerate insight into cardiac signaling networks, *Circ Res* 108 (1) (2011) 85–97. <http://dx.doi.org/10.1161/circresaha.110.223602>.
- [59] Lee, B-K Computational fluid dynamics in cardiovascular disease, *Korean Circ J* 41 (8) (2011) 423. <http://dx.doi.org/10.4070/kcj.2011.41.8.423>.
- [60] McGinty, S A decade of modelling drug release from arterial stents, *Math Biosci* 257 (2014) 80–90. <http://dx.doi.org/10.1016/j.mbs.2014.06.016>.
- [61] Garmaroudi, FS Handy, DE Liu, Y-Y Loscalzo, J Systems pharmacology and rational polypharmacy: nitric oxide-cyclic GMP signaling pathway as an illustrative example and derivation of the general case, *PLOS Comput Biol* 12 (3) (2016) e1004822. <http://dx.doi.org/10.1371/journal.pcbi.1004822>.
- [62] Davies, MR Wang, K Mirams, GR Caruso, A Noble, D Recent developments in using mechanistic cardiac modelling for drug safety evaluation, *Drug Discov Today* (2016) In Press. <http://dx.doi.org/10.1016/j.drudis.2016.02.003>.
- [63] Mishra, H Polak, S Jamei, M Rostami-Hodjegan, A Interaction between domperidone and ketoconazole: toward prediction of consequent QTc prolongation using purely in vitro information, *CPT Pharmacometrics Syst Pharmacol* 3 (8) (2014) e130. <http://dx.doi.org/10.1038/psp.2014.26>.

- [64] Fitzgerald, JB Schoeberl, B Nielsen, UB Sorger, PK Systems biology and combination therapy in the quest for clinical efficacy, *Nat Chem Biol* 2 (9) (2006) 458–66. <http://dx.doi.org/10.1038/nchembio817>.
- [65] Palmér, R Nyman, E Penney, M Marley, A Cedersund, G Agoram, B Effects of IL-1 β -blocking therapies in type 2 diabetes mellitus: a quantitative systems pharmacology modeling approach to explore underlying mechanisms, *CPT Pharmacometrics Syst Pharmacol* 3 (6) (2014) e118. <http://dx.doi.org/10.1038/psp.2014.16>.
- [66] Pálsson, S Hickling, TP Bradshaw-Pierce, EL Zager, M Jooss, K The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models, *BMC Syst Biol* 7 (2013) 95. <http://dx.doi.org/10.1186/1752-0509-7-95>.
- [67] Demin, O Karelina, T Svetlichniy, D Metelkin, E Speshilov, G Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors, *CPT Pharmacometrics Syst Pharmacol* 2 (2013) e74. <http://dx.doi.org/10.1038/psp.2013.49>.
- [68] Dunn, S-J Nätthke, IS Osborne, JM Computational models reveal a passive mechanism for cell migration in the crypt, *PLoS ONE* 8 (11) (2013) e80516. <http://dx.doi.org/10.1371/journal.pone.0080516>.
- [69] Leber, A Viladomiu, M Hontecillas, R Abedi, V Philipson, C Hoops, S Systems modeling of interactions between mucosal immunity and the gut microbiome during clostridium difficile infection, *PLOS ONE* 10 (7) (2015) e0134849. <http://dx.doi.org/10.1371/journal.pone.0134849>.
- [70] Ghosh, S Matsuoka, Y Asai, Y Hsin, K-Y Kitano, H Software for systems biology: from tools to integrated platforms, *Nat Rev Genet* (2011) <http://dx.doi.org/10.1038/nrg3096>.
- [71] Ghosh, S Matsuoka, Y Asai, Y Hsin, K-Y Kitano, H Toward an integrated software platform for systems pharmacology, *Biopharm Drug Dispos* 34 (9) (2013) 508–26. <http://dx.doi.org/10.1002/bdd.1875>.
- [72] Kanehisa, M Goto, S KEGG: kyoto encyclopedia of genes and genomes, *Nucleic Acids Res* 28 (1) (2000) 27–30. <http://dx.doi.org/10.1093/nar/28.1.27>.
- [73] Joshi-Tope, G Reactome: a knowledgebase of biological pathways, *Nucleic Acids Res* 33 (Database issue) (2004) D428–D432. <http://dx.doi.org/10.1093/nar/gki072>.
- [74] Shannon, P Cytoscape: a software environment for integrated models of biomolecular interaction networks, *Genome Res* 13 (11) (2003) 2498–504. <http://dx.doi.org/10.1101/gr.1239303>.
- [75] Funahashi, A Morohashi, M Kitano, H Tanimura, N CellDesigner: a process diagram editor for gene-regulatory and biochemical networks, *BIOSILICO*, 1 (5) (2003) 159–62. [http://dx.doi.org/10.1016/s1478-5382\(03\)02370-9](http://dx.doi.org/10.1016/s1478-5382(03)02370-9).
- [76] Hoops, S Sahle, S Gauges, R Lee, C Pahle, J Simus, N COPASI—a COMplex PAtchway Simulator, *Bioinformatics* 22 (24) (2006) 3067–74. <http://dx.doi.org/10.1093/bioinformatics/btl485>.
- [77] Core Team, R R: A language and environment for statistical computing, R foundation for statistical computing, Vienna, Austria. 2016, <https://www.R-project.org/>.
- [78] Eaton, JW Bateman, D Hauberg, S Wehbring, R GNU octave version 4.0.0 manual: a high-level interactive language for numerical computations, 2015, <http://www.gnu.org/software/octave/doc/interpreter>.
- [79] MATLAB and Simulink product families, The MathWorks, Inc., Natick, Massachusetts, United States, 2016.
- [80] Jamei, M Marciniak, S Feng, K Barnett, A Tucker, G Rostami-Hodjegan, A The simcyp® population-based ADME simulator, *Expert Opin Drug Metab Toxicol* 5 (2) (2009) 211–23. <http://dx.doi.org/10.1517/17425250802691074>.
- [81] Leil, TA Ermakov, S Editorial: the emerging discipline of quantitative systems pharmacology, *Front Pharmacol* 6 (2015) 129. <http://dx.doi.org/10.3389/fphar.2015.00129>.
- [82] Hucka, M Finney, A Sauro, HM Bolouri, H Doyle, JC The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models, *Bioinformatics* 19 (4) (2003) 524–31. <http://dx.doi.org/10.1093/bioinformatics/btg015>.
- [83] Swat, MJ Moodie, S Wimalaratne, SM Kristensen, NR Lavielle, M Pharmacometrics markup language (PharmML): opening new perspectives for model exchange in drug development, *CPT Pharmacometrics Syst Pharmacol* 4 (6) (2015) 316–9. <http://dx.doi.org/10.1002/psp4.57>.
- [84] Harnisch, L Matthews, I Chard, J Karlsson, M Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development, *CPT Pharmacometrics Syst Pharmacol* 2 (2013) e34. <http://dx.doi.org/10.1038/psp.2013.10>.
- [85] Hutchinson, L Kirk, R High drug attrition rates—where are we going wrong? *Nat Rev Clin Oncol* 8 (4) (2011) 189–90. <http://dx.doi.org/10.1038/nrclinonc.2011.34>.
- [86] Cucurull-Sanchez, L Spink, KG Moschos, SA Relevance of systems pharmacology in drug discovery, *Drug Discov Today* 17 (13–14) (2012) 665–70. <http://dx.doi.org/10.1016/j.drudis.2012.01.015>.
- [87] Benson, N van der Graaf, PH The rise of systems pharmacology in drug discovery and development, *Future Med Chem* 6 (16) (2014) 1731–4. <http://dx.doi.org/10.4155/fmc.14.66>.
- [88] Leil, TA Bertz, R Quantitative systems pharmacology can reduce attrition and improve productivity in pharmaceutical research and development, *Front Pharmacol* 5 (2014) <http://dx.doi.org/10.3389/fphar.2014.00247>.
- [89] Vicini, P van der Graaf, PH Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan? *Clin Pharmacol Ther* 93 (5) (2013) 379–81. <http://dx.doi.org/10.1038/clpt.2013.40>.